Morpholine derivatives and their use as antagonists of tachikinins

Abstract

PCT No. PCT/GB95/00983 Sec. 371 Date Nov. 1, 1996 Sec. 102(e) Date Nov. 1, 1996 PCT Filed May 1, 1995 PCT Pub. No. WO95/30674 PCT Pub. Date Nov. 16, 1995The present invention relates to compounds of formula (I): wherein X is N or CH; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of p articular use in the treatment of pain, inflammation, migraine and emesis. <IMAGE> (I)

We claim: 
     
       1. A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof: ##STR11## wherein X is N. 
     
     
       2. The compound: 2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine; or a pharmaceutically acceptable salt or prodrug thereof.   
     
     
       3. A pharmaceutical composition comprising a compound as claimed in claim 1 in association with a pharmaceutically acceptable carrier or excipient. 
     
     
       4. A method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof. 
     
     
       5. A method according to claim 4 for the treatment or prevention of pain or inflammation. 
     
     
       6. A method according to claim 4 for the treatment or prevention of migraine. 
     
     
       7. A method according to claim 4 for the treatment or prevention of emesis.